Shares of Brooklyn ImmunoTherapeutics Inc (NYSE:BTX - Get Free Report) were down 0.1% during trading on Monday . The company traded as low as $7.06 and last traded at $7.13. Approximately 564,560 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 743,693 shares. The stock had previously closed at $7.14.
Analyst Ratings Changes
Separately, Wall Street Zen began coverage on shares of Brooklyn ImmunoTherapeutics in a research note on Saturday, May 17th. They issued a "hold" rating on the stock.
Read Our Latest Stock Analysis on Brooklyn ImmunoTherapeutics
Brooklyn ImmunoTherapeutics Price Performance
The business's 50-day simple moving average is $6.42 and its two-hundred day simple moving average is $3.82. The stock has a market cap of $421.19 million, a price-to-earnings ratio of -3.15 and a beta of 4.61.
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Stories
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
